Tenet Healthcare Corporation (THC)
NYSE: THC · Services-General Medical & Surgical Hospitals, NEC · Dallas, TX
Our rating: Positive
Positive reaffirmed at $273.25, moderate conviction, October 30, 2026.
Breaks if: The Positive call rests on durable free-cash-flow generation and a reasonable multiple. It breaks if trailing-twelve-month free cash flow falls below $1.8B at either of the next two quarterly earnings prints — that would signal that labor or reimbursement pressure has structurally impaired the cash conversion that anchors the valuation thesis. Separately, if reported total revenue growth turns negative for two consecutive quarters, the franchise-stability argument dissolves and the rating moves toward Neutral. A re-rate to Conviction would require revenue growth accelerating above 5% for two straight quarters alongside free cash flow holding at or above $2.5B, demonstrating that volume and pricing can compound at a rate the current multiple does not capture.
Key figures
| Market value | $20.9B |
|---|---|
| Revenue, last 12 months | $22.2B |
| Net income, last 12 months | $3.8B |
| Free cash flow, last 12 months | $3.3B |
| Price to earnings | 5.5× |
| Free cash flow yield | 15.9% |
| Dividend yield | 0.0% |
| Operating margin | 24.4% |
| Return on equity | 80.7% |
| Beta to the S&P 500 | 0.77 |
| Volatility, annualized | 41.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $5.6B | 6.5% | $12.41 | $1.1B |
| June 30, 2026 | $5.6B | 6.8% | $9.84 | $417M |
| March 31, 2026 | $5.4B | 2.8% | $8.01 | $1.5B |
| December 31, 2025 | $5.5B | 8.9% | $4.21 | $367M |
| September 30, 2025 | $5.3B | 3.2% | $3.86 | $778M |
| June 30, 2025 | $5.3B | 3.2% | $3.14 | $743M |
| March 31, 2025 | $5.2B | −2.7% | $4.27 | $642M |
| December 31, 2024 | $5.1B | −6.0% | $3.43 | −$661M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $5.87B: Claude 72%, Gemini 85%, Mistral 55%
- Diluted earnings per share are at least $4.21: Claude 62%, Gemini 95%, Mistral 90%
- Free cash flow for the quarter is at least $0.37B: Claude 61%, Gemini 80%, Mistral 70%
- Backlog at the end of the quarter is at least $0.73B: Claude 35%, Gemini 20%, Mistral 40%
14 ledger entries and 85 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.